Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03962465
Title Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (ALL 001)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Virginia
Indications

lymphoblastic lymphoma

B-cell adult acute lymphocytic leukemia

Therapies

Daunorubicin + Inotuzumab ozogamicin + Pegaspargase + Prednisone + Vincristine Sulfate

Daunorubicin + Inotuzumab ozogamicin + Prednisone + Vincristine Sulfate

Cytarabine

Methotrexate

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.